Browse CD9

Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein Cell membrane Multi-pass membrane protein
Domain PF00335 Tetraspanin family
Function

Involved in platelet activation and aggregation. Regulates paranodal junction formation. Involved in cell adhesion, cell motility and tumor metastasis. Required for sperm-egg fusion.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0007043 cell-cell junction assembly
GO:0007272 ensheathment of neurons
GO:0007338 single fertilization
GO:0007342 fusion of sperm to egg plasma membrane
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008366 axon ensheathment
GO:0009414 response to water deprivation
GO:0009415 response to water
GO:0009566 fertilization
GO:0010001 glial cell differentiation
GO:0010035 response to inorganic substance
GO:0010927 cellular component assembly involved in morphogenesis
GO:0014003 oligodendrocyte development
GO:0021782 glial cell development
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030168 platelet activation
GO:0030913 paranodal junction assembly
GO:0031623 receptor internalization
GO:0032288 myelin assembly
GO:0034329 cell junction assembly
GO:0034330 cell junction organization
GO:0042063 gliogenesis
GO:0042552 myelination
GO:0043112 receptor metabolic process
GO:0044801 single-organism membrane fusion
GO:0045026 plasma membrane fusion
GO:0045055 regulated exocytosis
GO:0045216 cell-cell junction organization
GO:0048709 oligodendrocyte differentiation
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0055094 response to lipoprotein particle
GO:0055098 response to low-density lipoprotein particle
GO:0061025 membrane fusion
GO:0071402 cellular response to lipoprotein particle stimulus
GO:0071404 cellular response to low-density lipoprotein particle stimulus
Molecular Function GO:0005178 integrin binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0016324 apical plasma membrane
GO:0030055 cell-substrate junction
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030141 secretory granule
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030667 secretory granule membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0031091 platelet alpha granule
GO:0031092 platelet alpha granule membrane
GO:0045177 apical part of cell
GO:0045334 clathrin-coated endocytic vesicle
GO:0098552 side of membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1643685: Disease
R-HSA-1187000: Fertilization
R-HSA-109582: Hemostasis
R-HSA-5663205: Infectious disease
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-1474165: Reproduction
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
R-HSA-1300652: Sperm
R-HSA-5339562: Uptake and actions of bacterial toxins
R-HSA-5336415: Uptake and function of diphtheria toxin
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21172865MelanomaPromote immunity (T cell function)CD9(pos)Siglec-H(low) pDC secrete IFN-α when stimulated with TLR agonists, induce CTLs, and promote protective antitumor immunity. By contrast, CD9(neg)Siglec-H(high) pDC secrete negligible amounts of IFN-α, induce Foxp3(+) CD4(+) T cells, and fail to promote antitumor immunity.
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.360.54
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0350.992
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6280.778
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0550.876
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0940.967
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.010.997
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2170.703
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0770.968
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5640.795
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4090.863
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0690.985
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0450.681
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD9
NameCD9 molecule
Aliases BA2; TSPAN29; MRP-1; motility related protein-1; MIC3; CD9 antigen (p24); BTCC-1; DRAP-27; TSPAN-29; 5H9 ant ......
Chromosomal Location12p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CD9.
ID Name Drug Type Targets #Targets
DB05398C31GSmall MoleculeCD91